Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alterity TherapeuticsFRA:PBN +3.97%30 Current Ratio is 0.00 as of Mar. 2026. GuruFocus rates FRA:PBN with a GF Score™ of 30/100. Among 1,411 Biotechnology companies, Alterity Therapeutics ranks better than 93.41% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Alterity Therapeutics's current ratio for the quarter that ended in Mar. 2026 was 0.00.
Alterity Therapeutics has a current ratio of 0.00. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Alterity Therapeutics has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Alterity Therapeutics's Current Ratio or its related term are showing as below:
FRA:PBN'
s Current Ratio Range Over the Past 10 Years
Min: 3.54 Med: 7.07 Max: 21.98
Current: 12.98
During the past 13 years, Alterity Therapeutics's highest Current Ratio was 21.98. The lowest was 3.54. And the median was 7.07.
FRA:PBN's Current Ratio is ranked better than 93.41% of 1411
companies
in the Biotechnology industry
Industry Median: 3.85
vs FRA:PBN: 12.98
Alterity Therapeutics (FRA:PBN) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Alterity Therapeutics Current Ratio Related Terms
Alterity Therapeutics Current Ratio Historical Data
* Premium members only.
The historical data trend for Alterity Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PBN vs VRTX, REGN, RVMD: Current Ratio Comparison
For the Biotechnology subindustry, Alterity Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alterity Therapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alterity Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Alterity Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alterity Therapeutics (FRA:PBN) has a Current Ratio of 0.00 as of Mar. 2026. Over the past decade, Alterity Therapeutics' Current Ratio has ranged from 3.54 to 21.98. According to the industry distribution chart, Alterity Therapeutics ranks #93 out of 1411 companies in the Biotechnology industry, placing it in the top 6.6%.
Is Alterity Therapeutics' Current Ratio too high?
Alterity Therapeutics' current Current Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 3.54 to a high of 21.98. Based on the distribution chart, Alterity Therapeutics ranks #93 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Alterity Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Alterity Therapeutics' Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alterity Therapeutics ranks #93 out of 1411 companies for Current Ratio. This places Alterity Therapeutics in the top 7% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.85. Historically, Alterity Therapeutics' own Current Ratio has ranged from 3.54 to 21.98 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.85, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alterity Therapeutics's current Current Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alterity Therapeutics stock overvalued right now?
Alterity Therapeutics (FRA:PBN) has a current Current Ratio of 0.00. The current Current Ratio is 0.00. Alterity Therapeutics' overall GF Score™ is 30/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Alterity Therapeutics (FRA:PBN), the current Current Ratio is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
30GF Score
Get the complete analysis for FRA:PBN
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PBN has been successfully added to your 
